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Drug Watch
New To 
Market
New Generics
CPSInsider 
CPS Insider is produced by the  
University of Massachusetts 
Medical School’s Clinical Pharmacy 
Services division and distributed  
to our clients quarterly.
New To 
Market
July-September 2011
Information available at www.fda.gov/cder/ogd/.
• Budesonide capsules                  
 (Entocort® EC)
Launched: 6/23/11
• Ketoconazole foam 2% (Extina®)* 
       Launched: 8/30/11
• Levonorgestrel 90 mcg/ethinyl 
       estradiol 20 mcg tablets (Lybrel®)
Approval Date: 6/6/11 
Launch Date: TBD
• Levonorgestrel 0.15 mg/ethinyl 
        estradiol 0.03 mg and ethinyl  
        estradiol 0.01 mg tablets 
        (Seasonique®)† 
Launched: 7/28/11   
• Oxymorphone HCl extended 
        release tablets (Opana® ER)‡ 
        Launched: 7/15/11
               
* Perrigo Co. has 180-day market exclusivity.
† Teva Pharmaceuticals launched an authorized 
           generic.
‡         Actavis Pharmaceuticals has launched generic 
           oxymorphone HCl ER 7.5 mg and 15 mg. Watson 
           Pharmaceuticals is expected to launch oxymorphone  
           HCl ER 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg in 
           September 2012.
Noteworthy
Comparative 
Effectiveness Research 
in Health Care Reform
What’s New at UMass 
Medical School?
CPS Optimizes 
Pharmacotherapy for 
Patients with Acquired 
Brain Injury
    Arcapta™ (indacaterol) 
    Approved: 7/1/2011 
    Mfr: Novartis Pharmaceuticals
    Formulation: Inhalation Powder
    Cost (AWP): $196/30 days
Arcapta™ Neohaler™ (indacaterol), a 
long-acting β2-adrenergic agonist (LABA), is 
approved as a maintenance bronchodilator for 
patients with chronic obstructive pulmonary 
disease (COPD), including emphysema and 
chronic bronchitis. Indacaterol is formulated as 
a 75 mcg capsule approved for once daily oral 
inhalation through the Neohaler™ device. 
Three dose-ranging trials demonstrated no 
clear difference in forced expiratory volume in 
one second (FEV1) between indacaterol 75 mcg 
daily and higher doses (150 mcg, 300 mcg, and 
600 mcg daily). Six double-blind, randomized, 
controlled trials (N=5,474) compared 
indacaterol in doses 75 mcg and higher to 
placebo and/or an active control (salmeterol, 
formoterol, or tiotropium) in patients with 
COPD. The primary efficacy endpoint for all six 
trials was based on the 24-hour postdose trough 
FEV1 at 12 weeks. Of these six trials, only two 
trials (N=641) evaluated the efficacy of 
indacaterol at the FDA-approved dose of 75 
mcg daily. Results from these two trials 
demonstrated a mean difference in trough FEV1 
of 130 mL between indacaterol and placebo at 
12 weeks (P<0.001). 
Common adverse reactions include cough, 
nasopharyngitis, and headache. Indacaterol has 
the same boxed warning as other LABAs for 
increased asthma-related death. Although not 
approved for asthma, indacaterol has the 
advantage of once daily dosing when compared 
to other LABAs dosed twice daily. 
        Potiga™ (ezogabine)
        Approved: 6/10/2011
        Mfr: Valeant Pharmaceuticals
        Formulation: Tablet
        Cost (AWP): Unavailable
Potiga™ (ezogabine) is a potassium channel 
opener indicated as add-on therapy for partial-
seizures in adults ages 18 and older. Ezogabine 
may stabilize the resting membrane potential 
and lower brain excitability by facilitating the 
action of neuronal KCNQ channels. It is initiated 
at 100 mg three times daily and increased by 50 
mg per dose at weekly intervals to a maintenance 
dose of 200 mg to 400 mg three times daily.
In three randomized trials (N=1,239) 
comparing ezogabine to placebo, one primary 
endpoint required by the FDA was the median 
percent reduction in monthly total partial-
seizure frequency following 18 weeks of 
treatment. The RESTORE 1 trial showed a greater 
reduction in median monthly total partial-seizure 
frequency with ezogabine 1,200 mg  daily 
compared to placebo (44.3 versus 17.5 percent, 
P<0.001). A dose-ranging study showed a greater 
median reduction in monthly total partial-seizure 
frequency from baseline for ezogabine 600 mg, 
900 mg, and 1200 mg daily versus placebo (23, 
29, and 35 versus 13 percent, P<0.001 for all). 
Common adverse reactions include dizziness, 
somnolence, and fatigue. The FDA requires a 
REMS for ezogabine due to the risk of acute 
urinary retention. As the first potassium channel 
opener indicated as an adjunct for partial-
seizures, it will likely compete with Lyrica® 
(pregabalin) and Keppra® (levetiracetam) as 
adjuncts for partial-seizures. Ezogabine is 
anticipated to be available at the end of the year 
after the DEA has evaluated its abuse potential 
and determined a controlled substance schedule.
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From The Hill
•	 Botox® (onabotulinumtoxinA)                                    
 On Aug. 24, 2011, Botox® (onabotulinumtoxinA) was approved for the treatment of urinary  
 incontinence resulting from detrusor overactivity in adults with neurologic conditions  
 (e.g., spinal cord injury,  multiple sclerosis) and with inadequate response or intolerance to  
 an anticholinergic medication. In addition, onabotulinumtoxinA is indicated for the   
 treatment of blepharospasms associated with dystonia, cervical dystonia, migraine   
 prophylaxis, severe axillary hyperhidrosis, strabismus, and upper limb spasticity.   
 Previously, no options were available for patients intolerant to anticholinergics.
•	 Omnitrope® (somatropin)
  On July 22, 2011, Omnitrope® (somatropin) was approved for the treatment of pediatric
       patients with growth failure associated with Turner Syndrome. In addition, somatropin is 
       indicated for the treatment of children with growth failure due to growth hormone 
       deficiency, Prader-Willi Syndrome, Small for Gestational Age, and Idiopathic Short 
       Stature. Other somatropin formulations indicated for growth failure associated with 
       Turner Syndrome  include Genotropin®, Humatrope®, Norditropin®, and Nutropin®.
•	 Pegasys®/Copegus® (peginterferon alfa-2a/ribavirin)    
 On Aug. 22, 2011, Pegasys®/Copegus® (peginterferon alfa-2a/ribavirin) was approved for  
 the treatment of hepatitis C in children and adolescents ages 5 to 17 who have   
 compensated liver disease and no prior history of interferon alpha therapy.  PegIntron®/ 
 Rebetol® (peginterferon alfa-2b/ribavirin) is approved for the treatment of hepatitis C in  
 children ages 3 and older with compensated liver disease.
• Lupron Depot-Ped®            
 (leuprolide acetate) 
     11.25 mg and 30 mg IM injection                       
     Approved: 8/15/2011
• Orencia® (abatacept)
 125 mg/mL SC injection                                              
     Approved: 7/29/2011 
•	 Zyclara® (imiquimod)
 2.5% cream
 Approved: 7/19/2011                                                         
Pharmacotherapy for the Treatment of Acute Bipolar II Depression: Current Evidence from the Journal of Clinical Psychiatry
In March 2011, Swartz et al published a review in the Journal of 
Clinical Psychiatry citing the need for an update on treatment 
guidelines for Bipolar (BP) II Depression. The authors state that 
earlier treatment guidelines have few specific recommendations for 
BP II, leading clinicians to treat BP II depression based primarily on 
trials for BP I. Additionally, the authors explain that patients with BP 
II depression can present with both hypomanic and depressive 
symptoms resulting in more “mixed” episodes throughout the 
course of illness, alluding to the need for evidence-based treatment 
options specific to this population. The American Psychiatric 
Association (APA) last published a guideline for the treatment of BP 
depression in 2002, followed by a guideline watch with 
pharmacotherapy updates in 2005. For the treatment of BP 
depression, the APA provides evidence to support the use of lithium, 
lamotrigine, and adjunctive therapy with paroxetine. The guideline 
watch provided updated evidence for acute BP I depression 
treatment to include an olanzapine and fluoxetine fixed 
combination, quetiapine, and lamotrigine. Both of these guidelines 
include limited trials that are specific to BP II depression. 
     The Swartz review includes 21 studies, 90 percent of which were 
published after 2006, that evaluated quetiapine, lamotrigine, 
lithium, antidepressants, pramipexole, modafinil, and valproate. 
Quetiapine was evaluated in a post hoc analysis of data from two 
combined, multicenter, randomized, double-blind, placebo-
controlled studies (BOLDER I and II; N=321) in patients with BP  II.       
Patients receiving quetiapine 300 mg or 600 mg daily compared to 
placebo demonstrated greater mean reduction in Montgomery-Asberg 
Depression Rating Scale scores (17.1 and 17.9 versus 13.3 points) and 
remission rates (39.3 and 37.7 versus 20.4 percent) after eight weeks 
(P-values not reported). BOLDER I and II provide evidence for the use of 
quetiapine as a first-line treatment option. 
In a combined analysis of five double-blind, placebo-controlled 
trials, lamotrigine was found to have a modest advantage versus 
placebo in patients with BP II depression. A meta-analysis and meta-
regression analysis of the same studies showed that lamotrigine was 
“superior” versus placebo in patients with Hamilton Depression Rating 
Scale (HDRS) scores greater than 24 (P-value not reported). A HDRS 
score equal to or greater than 23 is indicative of very severe depression. 
These studies provide evidence to support the use of lamotrigine as a 
preferred second-line agent for treatment of BP II depression. Lithium, 
pramipexole, and certain SSRIs are currently recommended as other 
second-line agents, but data supporting their efficacy is often based on 
lower quality evidence. Both valproate and modafinil use in BP II 
depression are not recommended due to inadequate data.
This review provides an update for the treatment of patients with 
acute BP II depression, as recommendations are based on new trials 
since the last guideline update. Additional randomized, controlled 
trials focusing on acute and maintenance treatment of BP II depression 
with longer follow-up are necessary to improve the quality of evidence 
used to guide clinical decision making. 
Information available at www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry. 2011;72(3):356-366.
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Advisories
FDA  Action Due to Risk Associated with 
Avandia
On May 19, 2011, the FDA announced that 
Avandia® (rosiglitazone), Avandamet® 
(rosiglitazone/metformin), and Avandaryl® 
(rosiglitazone/glimepiride) will be removed 
from retail pharmacy shelves in November 
due to the increased risk of heart attack. It 
has been estimated that between 66,000 and 
200,000 patients treated with rosiglitazone 
have experienced heart problems, leading to 
death in some patients, while taking the 
agent. By Nov. 18, 2011, the FDA will require 
practitioners to be certified to prescribe 
rosiglitazone-based products. Rosiglitazone 
will be available only to patients who meet all 
of the following criteria: 
   • Can be treated safely with the agent 
   • Have blood glucose levels that cannot be          
 controlled with other drugs 
   • Prefer rosiglitazone to other agents after  
 being informed of the risks.  
In addition, rosiglitazone prescriptions must 
be filled through mail order pharmacies.  
Long-term Use of High-Dose 
Fluconazole Associated with Birth 
Defects
On Aug. 3, 2011, the FDA warned against 
pregnant women using long-term, 
high-dose Diflucan® (fluconazole), 400 
mg to 800 mg daily. Several published 
case reports describe the development 
of birth defects with the use of 
fluconazole in the first trimester. 
Exposed infants can present with short, 
broad heads; abnormal development of 
the skullcap; cleft palate; and 
congenital heart disease. The birth 
defects do not appear to be associated 
with a single, low dose of fluconazole 
150 mg, typically used for the treatment 
of vaginal candidiasis. The pregnancy 
category for fluconazole has been 
reclassified from C to D for all 
therapeutic indications except for 
vaginal candidiasis, which remains 
category C. Health care providers should 
inform patients with regard to the fetal 
risk linked to high-dose fluconazole.
High Doses of Citalopram May Increase the Risk 
of QT Prolongation
On Aug. 24, 2011, the FDA alerted health care 
providers against prescribing citalopram in 
doses greater than 40 mg daily, which can 
prolong the QT interval in a dose-dependent 
manner and lead to a fatally abnormal heart 
rhythm such as Torsade de Pointes. The risk of 
QT prolongation is increased in patients with 
underlying heart conditions, such as 
congestive heart failure and 
bradyarrhythmias, and in patients 
predisposed to low blood levels of potassium 
and magnesium. Additionally, citalopram 
should not be used in patients with congenital 
long QT syndrome. The Dosage and 
Administration sections of the prescribing 
information for citalopram has been revised 
to reflect the new dose recommendation due 
to the risk of QT prolongation and inadequate 
evidence to support efficacy at doses greater 
than 40 mg daily. Lexapro® (escitalopram), 
may also cause QT prolongation but does not 
carry the same FDA warning as citalopram. 
The maximum recommended dose for 
escitalopram is 20 mg daily.
Federal
Drug Shortages in the U.S. Health Care System
The U.S. health care system has experienced recent drug 
shortages, primarily with intravenous chemotherapeutic agents 
and anti-infectives, but also common outpatient generic 
medications including metformin, amphetamine mixed salts, 
and oxycodone formulations. This shortage is an extension of a 
problem that began in 2010. Currently, 200 medications are 
listed in short supply, a number that has tripled in the past five 
years. This scarcity is driven by issues related to quality and 
manufacturing, delays and capacity, discontinuations, and 
supplies of raw material. The shortage has resulted in increased 
medication prices and limited patient access to certain 
medications. On Sep. 26, 2011, the FDA held a meeting with 
trade groups, physician organizations, drug manufacturers, 
group purchasing organizations, distributors, and patients  to 
discuss solutions for the shortage. Proposed solutions include 
requiring manufacturers to give early warnings of potential 
shortages and creating a national stockpile of drugs in short 
supply through a nonprofit organization. For managed care 
entities, this shortage may lead to increased coverage of 
nonformulary and branded medications to replace generics in 
short supply. 
 
State-Controlled Health Insurance Exchanges
State-based health insurance exchanges (HIX) will allow 
uninsured individuals and small businesses to purchase private 
health insurance plans in a competitive marketplace as of 2014. 
States can receive federal funding to develop their own exchanges 
or accept a federally mandated version designed by the Health and 
Human Services (HHS) as part of the Affordable Care Act (ACA). 
HHS has awarded $185 million to the District of Columbia and 13 
states with approved HIX legislation. With their own HIX 
initiatives, states can negotiate prices and determine parameters 
for plan qualification. Texas and Montana are taking steps to avoid 
the federal mandate, but South Carolina, Kansas, and Oklahoma 
have rejected federal dollars. Massachusetts and Utah established 
exchanges prior to the ACA. The Health Connector, which runs the 
Massachusetts HIX, and the Blue Cross Blue Shield Foundation are 
developing an online toolkit to assist other states in establishing 
their HIX. A federally mandated HIX would require HHS to assume 
responsibility for multiple exchanges. In preparation, HHS 
gathered officials from the District of Columbia and 46 states to 
propose HIX models with varying federal-state participation. One 
proposal requires states to control consumer affairs and HHS to 
determine member eligibility and enrollment.
NoteworthyPipeline
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Dapagliflozin
 Dapagliflozin, a sodium-dependent glucose 
co-transporter 2 inhibitor, is currently being 
evaluated for the treatment of type 2 
diabetes. In an extension of a 52-week, Phase 
III randomized, controlled trial, treatment 
with dapagliflozin added to metformin resulted 
in sustained HbA1c reduction at 104 weeks 
compared to baseline (-0.32 percent, 95 
percent CI -0.42 to -0.21). On July 19, 2011, an 
FDA advisory committee voted 9-6 against 
recommending approval of dapagliflozin citing 
safety concerns.  Pooled data from 11 Phase III 
trials showed nine cases each for bladder and 
breast cancers reported in patients receiving 
dapagliflozin compared to one case of each 
cancer in the placebo group (0.16 versus 0.03 
percent, P=0.15; 0.4 versus 0.09 percent, 
P=0.27; respectively). An FDA response is 
expected by Oct. 28, 2011. 
Safinamide
 Safinamide, a monoamine oxidase B 
inhibitor being studied as adjunctive therapy in 
Parkinson’s disease (PD), decreases dyskinesia 
by suppressing dopamine reabsorption and 
glutamate release. A Phase III extension study 
evaluated safinamide as adjunct therapy to 
levodopa in advanced stage PD. At 24 months, 
treatment with safinamide 50 mg and 100 mg 
resulted in an increase in “ON” time, or period 
of best motor function, versus placebo (1.01 
and 1.18 versus 0.34 hours, P=0.0031 and 
P=0.0002, respectively). Two ongoing Phase III 
trials, MOTION and SETTLE, are currently 
evaluating the safety and efficacy of 
safinamide, with MOTION expected to have an 
18-month extension trial. A new drug 
application submission is planned for 2012.
The Massachusetts Rehabilitation Commission, MassHealth, and 
UMass Medical School, offer two acquired brain injury (ABI) waivers: 
one with residential habilitation for patients in a community setting 
requiring supervision (ABI-RH) and one for patients who can live at 
home or someone else’s home (ABI-N). This program is available to 
Medicaid-eligible patients who have experienced an ABI at age 22 or 
older, have resided in a nursing facility or chronic rehabilitation 
center for at least 90 days, and have service needs limited to 
$194,486 per year for ABI-RH and $99,890 per year for ABI-N. Causes 
of ABI include stroke, brain trauma, infections (e.g., encephalitis), 
brain tumor, or anoxia. These patients struggle with administering 
their medications and remembering  complex regimens. 
         At UMass Medical School’s Clinical Pharmacy Services (CPS), 
pharmacists visit patients in home and community settings to 
provide medication reviews and recommendations and to help 
minimize care costs. For example, CPS pharmacists visited a 
patient home in early 2011 and identified a case of drug-induced 
sedation. CPS recommended therapy modification that improved 
the member’s mental status and quality of life, while lessening 
the cost of care. As a new initiative, CPS also provides medication 
reviews for patients newly enrolled into the waiver.
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Comparative Effectiveness Research in Health 
Care Reform 
 In 2009, the Obama administration sponsored 
comparative effectiveness research (CER) after 
the enactment of the Patient Protection and 
Affordable Care Act. The Act established the 
Patient-Centered Outcomes Research Institute 
(PCORI), which will receive approximately $550 
million per year to fund and disseminate data 
from CER studies. This type of study is used to 
determine how medical initiatives in 
development compare to current standards of 
care. PCORI will also attempt to elevate the 
role of CER in the health care system.
 The Agency for Healthcare Research and 
Quality (AHRQ) Effective Health Care (EHC) 
Program currently manages a library of CER 
reviews dating back to 2005. The CER reviews, 
using study data from new or existing research, 
are developed in collaboration with researchers 
and academic institutions. A recent 2011 CER 
review evaluates oral medications used for the 
treatment of type 2 diabetes. The library of 
CERs is available at http://effectivehealthcare.
ahrq.gov/.
 To support translational CER for pharmacy 
and therapeutics committees and other drug 
policy decision makers, the Academy of 
Managed Care Pharmacy and the University of 
Arizona are hosting AHRQ grant-supported 
educational sessions at select conferences 
focused on the use of CERs in making coverage 
decisions. Other educational tools will be 
offered online and through publications.
 Managed care pharmacists are often directly 
responsible for formulary decisions based on 
limited information on drug cost, safety, and 
efficacy. The increased availability of CERs over 
time is likely to further strengthen robust 
evidence-based coverage decisions.
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Who We Are and What We Do
The University of Massachusetts Medical School’s Clinical Pharmacy Services is a comprehensive 
prescription drug management program developed in 1999 as part of the Medical School’s Commonwealth 
Medicine division, primarily to provide drug utilization review for Massachusetts Medicaid.  Today, we bring    
exceptional depth and experience in the development and implementation of unique, client-customized, 
managed care-related clinical pharmacy functions including, but not limited to, evidence-based formulary 
support, pharmacoeconomic modeling, drug utilization review, medication therapy management, clinical 
call center support, and provider/patient education. The CPS Insider is an educational resource produced 
quarterly to deliver critical information at the highest level of quality to our clients.  We hope that you find 
this resource of value, and we welcome your suggestions for improvement.
